GO
Loading...

Acquisitions

More

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106- billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- British lawmakers on Tuesday summoned bosses of U.S. drugmaker Pfizer to explain a $106 billion takeover bid for pharmaceutical firm AstraZeneca which has raised fears over UK jobs, research and intellectual property.

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106 billion takeover approach on Tuesday by predicting its revenues would rise 75 percent over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- Senior management from U.S. drugmaker Pfizer and British pharmaceutical firm AstraZeneca will be called before a British parliamentary committee to answer questions on a potential takeover deal, the committee chairman said on Tuesday.

  • LONDON, May 6- Representatives from U.S. drugmaker Pfizer and British pharmaceutical firm AstraZeneca will be called before a British parliamentary committee to discuss a potential takeover deal in the coming weeks, a committee spokesman said on Tuesday.

  • AstraZeneca acquired drug after buying Omthera in 2013. LONDON, May 6- AstraZeneca Plc has won U.S. approval for Epanova, a new pill for heart disease, providing a welcome- but relatively minor- piece of good news as it fights a $106 billion takeover approach from Pfizer Inc.

  • NEW YORK, May 5- Pfizer Inc's top officials said on Monday they are weighing all strategies, including potential hostile maneuvers, in the company's effort to seal a $106 billion takeover of British drugmaker AstraZeneca Plc.

  • Oncor avoided bankruptcy because of a credit provisions called a ring-fence put in place in 2007 to satisfy Texas legislators and regulators worried about the $40 billion debt created in the leveraged buyout by a group of private equity firms led by KKR& Co LP.

  • SYDNEY, May 5- Australian gas firm WestSide Corp Ltd on Monday rejected as undervalued a takeover offer from China's diversified energy company Landbridge Group Co Ltd that valued the company at A $177.6 million.

  • LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, opposition Labour party leader Ed Miliband said on Sunday. AstraZeneca rejected a 63 billion pound takeover bid from Pfizer on Friday, but the U.S. firm is expected to pursue its interest.

  • Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.

  • GE in talks to buy Alstom: Report     Thursday, 24 Apr 2014 | 6:09 AM ET

    Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.

  • Einhorn's new course     Tuesday, 22 Apr 2014 | 2:31 PM ET

    Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.

  • Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.

  • GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.

  • Novartis acquisition adds 'tremendous value'     Tuesday, 22 Apr 2014 | 6:45 AM ET

    GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.

  • PwC strikes deal to buy Booz     Thursday, 3 Apr 2014 | 7:16 AM ET

    Bob Moritz, PricewaterhouseCoopers chairman and senior partner, discusses the company's plan to boost its consulting business by extending its global reach.

  • Marriott completes deal to acquire Protea     Tuesday, 1 Apr 2014 | 8:16 AM ET

    Arne Sorenson, CEO & president of Marriott International, discusses his company's acquisition of the largest hotel company in Africa.

  • How activist investors influence M&A     Friday, 28 Mar 2014 | 8:16 AM ET

    Michael Carr, Goldman Sachs M&A group in the Americas, shares his thoughts on the role of activists in deal making and the outlook for mergers and acquisitions.

  • 'Poison Pill' inventor targets activism     Friday, 28 Mar 2014 | 7:34 AM ET

    Activism in the long-term is not only bad for shareholders but also bad for the economy as a whole, says Martin Lipton, Wachtell, Lipton, Rosen & Katz, expressing his views on shareholder activism. Also Lipton shares his thoughts on the two categories of hedge fund activism.